

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/832,929	04/12/2001	Craig A. Rosen	6832.0013-00	5241
22852 7	590 03/03/2005		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			ROBINSON, HOPE A	
LLP 901 NEW YOR	RK AVENUE, NW		ART UNIT	PAPER NUMBER
	WASHINGTON, DC 20001-4413		1653	

DATE MAILED: 03/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Supplemental	Application No.	Applicant(s)	
Supplemental Notice of Allowability	09/832,929	ROSEN ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Hope A. Robinson	1653	<u> </u>
The MAILING DATE of this communication appel All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	plication. If not include n will be mailed in due	ded e course. <b>THIS</b>
1. This communication is responsive to 2/23/05.			
2.  The allowed claim(s) is/are 1-21 and 26-29.			
3. The drawings filed on are accepted by the Examine	r.		
4. ☐ Acknowledgment is made of a claim for foreign priority ur  a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have			
2. ☐ Certified copies of the priority documents have		_	
3. ☐ Copies of the certified copies of the priority do	- · · ·		ation from the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the re	equirements
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			NOTICE OF
6. CORRECTED DRAWINGS ( as "replacement sheets") mus	st be submitted.		
(a) ☐ including changes required by the Notice of Draftspers		-948) attached	
1) ☐ hereto or 2) ☐ to Paper No./Mail Date	•		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the C	Office action of	
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t			e back) of
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAL i	must be submitted.	Note the
Attachment(s)	5 🗆 Norman (1.6) - 15	Saturat Appell 141 - 155	-O 450)
1. Notice of References Cited (PTO-892)	5. Notice of Informal F		U-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Da	te	
3. 🔲 Information Disclosure Statements (PTO-1449 or PTO/SB/0		ment/Comment	

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

of Biological Material

Information Disclosure Statements (PTO-1449 or PTO/SB/08),
 Paper No./Mail Date \_\_\_\_\_

 Examiner's Comment Regarding Requirement for Deposit

8. 

Examiner's Statement of Reasons for Allowance

1. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

- 2. Authorization of this Examiner's amendment was given in a telephone interview with Mr. Charles Van Horn on February 23, 2005.
- 3. The Specification has been amended as follows:

  Please replace the paragraph found on page 150, lines14-20 with the following paragraph:

For example, wherein the Therapeutic protein is hGH, EPO, alpha-IFN or beta-IFN, formulations containing the albumin fusion protein may be prepared taking into account the extended shelf-life of the albumin fusion protein in aqueous formulations. [[As exhibited in Table 2, most]] Most Therapeutic proteins are unstable with short shelf-lives after formulation with an aqueous carrier. As discussed above, the shelf-life of many of these Therapeutic proteins are markedly increased or prolonged after fusion to HA.

[Table 2]]

Application/Control Number: 09/832,929 Page 3

Art Unit: 1653

4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

## Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hope A. Robinson whose telephone number is 571-272-0957. The examiner can normally be reached on Monday-Friday from 9:00 a.m. to 6:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon P. Weber, can be reached at (571) 272-0925.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Art Unit: 1653

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Hope Robinson, MS **↓** 

Patent Examiner

JON WEBER
SUPERVISORY PATENT EXAMINER